The 180-day exclusivity period is the primary economic engine of the U.S. generic pharmaceutical industry. This six-month window creates a […]

The pharmaceutical industry faces a structural realignment of its economic foundations. Between 2025 and 2030, a “super-cliff” of patent expirations

Introduction: Beyond the Courtroom — Why Patent Litigation is the Ultimate Pharma Value Driver Let’s be direct. If you’re an

The pharmaceutical business model relies on a simple cycle. Companies invest billions into research, secure a period of market exclusivity

The global pharmaceutical industry currently faces a historic loss-of-exclusivity super-cycle. Between 2025 and 2030, an estimated $200 billion to $400

The pharmaceutical supply chain is a system where the loss of exclusivity for a brand-name drug creates a massive transfer

The pharmaceutical industry is approaching a singularity. Between 2025 and 2030, a wave of patent expirations—often described as the “super-cliff”—will

The foundational error in pharmaceutical valuation lies in conflating the statutory patent term with commercial exclusivity. Generalist investors and market

Big pharma used to treat loss of exclusivity as a weather event. You saw the date on the Gantt chart,